The creation of retatrutide, a novel dual activator targeting both GLP-1 and GIP receptors, represents a complex complicated synthetic process. Preliminary routes focused on amino acid chain fragment coupling, utilizing solid-phase production methodologies to build the long amino acid sequence. Subsequent research has explored different approaches,